Artificial intelligence (AI), using a simple blood test combined with standard brain images has, for the first time, been ...

Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

This study demonstrated progressive CP enlargement over time in individuals with RRMS, averaging 1.4% a year with significant variation per participant. CP enlargement correlated with the expansion of ...

Brain volume loss is a key marker of degeneration in multiple sclerosis, correlated with future disability progression. Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly ...

A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis.

WEDNESDAY, Dec. 17, 2025 (HealthDay News) — An over-the-counter supplement called lipoic acid might help slow the loss of gray matter in the brains of people with progressive multiple sclerosis (MS), ...

A new study from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, suggests positron emission tomography (PET) brain scans could reveal hidden inflammation ...

Your brain doesn't have to age on autopilot. New research shows we can slow—and potentially reverse—brain aging.

Lipoic acid did not improve patients’ walking speed, which was the main outcome being measured by researchers. But MRI scans revealed the supplement did appear to slow brain atrophy, researchers ...